Ling Chen | Professor
Guangzhou Medical University,Guangzhou, China

Dr. Ling CHEN received his medical degree from Shanghai Medical College (now affiliated with Fudan University) in 1984. He then entered the elite CUSBEA program and earned a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine in the United States in 1992. After completing his postdoctoral training at the Dana-Farber Cancer Institute, he served as an instructor at Harvard Medical School from 1994 to 1996.  Subsequently, he served as a Senior Research Fellow at Merck Research Laboratories, where he championed the Ad5-vectored T cell-based HIV/AIDS vaccine. In 2003, Dr. Chen moved to China to serve as the founding Director General of the Guangzhou Institute of Biomedicine and Health, a new entity of Chinese Academy of Sciences. Between 2009 and 2012, Dr. Chen served as Vice President of R&D China at GSK and subsequently as Vice President for Sanofi Pasteur China Vaccine R&D, before returning to academia in 2013. Dr Chen has over 200 publications on infectious diseases, vaccines and cancer research. He played a key role in developing an adenovirus-vectored nasal vaccine for SARS-CoV-2.  His recent research interests include mucosal vaccines, monoclonal antibodies and antibody repertoire, as well as novel shark-derived nanobodies for mucosal antiviral agents.